Interview

Plexo Capital's Lo Toney on backing emerging fund managers and the shift toward technical GPs

Sep 28, 2026 with Lo Toney

Key Points

  • Plexo Capital backs emerging fund managers by identifying GPs with technical depth from hyperscalers who can spot market gaps faster than traditional investors.
  • Seed and Series A rounds are growing faster than small funds can follow, forcing ownership targets down from five to ten percent to three percent or less within single deployment cycles.
  • Plexo's $18 billion Anthropic entry in January 2024 required LP conviction that the company would reach approximately $12 trillion in value, a bet Toney says the trajectory has supported.

Plexo Capital's Lo Toney on backing emerging fund managers and the shift toward technical GPs

Lo Toney founded Plexo Capital in 2018 after identifying a pattern at GV (Google Ventures): fund-one micro-VCs investing at pre-seed were delivering unique deal flow, and the most effective way to partner with them was to help with their fundraise. He spun Plexo out of GV's entrepreneur-in-residence program, bringing Alphabet in as anchor LP alongside Intel, Cisco, Royal Bank of Canada, Ford Foundation, and Mass Mutual.

The technical GP thesis

The most significant shift Toney identifies across the last decade is the profile of the best emerging GPs. They are meaningfully more technical than their predecessors. The edge, as he describes it, is specific: a GP who spent years inside a hyperscaler understands the technical limitations of current solutions well enough to know exactly what is missing, and can move immediately when a founder closes that gap. They also carry a calibrated sense of what A-teams and A-organizations look like, which matters as much as the market call.

Toney draws an explicit parallel to the product manager role, which he argues is the best pre-GP training available. A PM operates like a mini-CEO across engineering, marketing, and finance, and the analytical framework maps almost directly onto early-stage investing: what problem is being solved, what are the shortcomings of existing solutions, and how does distribution actually work.

His read on the current moment is that researcher spinouts are capturing all the attention, but the GP alpha may sit with former product managers who built at high-density engineering organizations and are now running small, focused funds.

“The GPs that are the best — especially in the age of AI — are much more technical even within the last ten years. I think that's the biggest evolution I've seen. They come in with a very unique perspective and the edge translates directly from their technical understanding of a problem they had to tackle within one of these technology companies. The flip side is being able to scale and keep that ownership stake as the companies now move so quickly through the financing rounds.”

The pro-rata squeeze

The structural challenge for emerging managers is well-defined. Seed and Series A rounds are scaling in size faster than small fund managers can follow, and the larger shops are moving earlier. Toney describes the progression: GPs went from SPVs to dedicated follow-on vehicles, but neither approach holds up when rounds jump in size rapidly and multi-stage firms are already present at the table. Ownership targets that made sense when funds were raised in 2024 — five to ten percent at pre-seed — are now being revised down to three percent or less within a single deployment period.

The Anthropic investment

Toney uses Plexo's Anthropic position as the clearest illustration of both the opportunity and the difficulty of navigating this environment. The deal came through a GP in the network, the same GP that had brought Plexo into Reddit. It was Plexo's first SPV, structured around the Series D that Menlo led, closing in January 2024. The entry valuation was $18 billion, which Toney describes as far beyond anything the firm had previously considered. His framing to LPs at the time was that the investment only made sense if Anthropic reached something in the range of $12 trillion in value. He notes, without elaborating, that the trajectory since has been supportive of that logic.

GP positioning and portfolio construction

Toney's selection criteria have sharpened around consistency of approach rather than sector or stage alone. He tracks whether GPs are chasing hot themes or showing a stable pattern in both the problem domain and the founder personality they back. The latter is a signal of genuine conviction and a predictor of non-overlapping deal flow across the Plexo portfolio, which is the explicit construction goal: cast as wide a net as possible by backing GPs with meaningfully different edges.

The value-add angle has also become more granular. Toney cites GPs who bring a specific network of product managers as a talent pipeline, and others who carry PR and communications expertise, which he argues matters more than investors typically acknowledge given how fast companies now scale into high-visibility positions. Higgs Field reaching $1 billion in revenue faster than any prior company is his example: founders are entering board rooms and state dinners years earlier than a Jobs or a Brin ever had to, without the equivalent runway to develop those instincts.

AI as operational leverage

Toney is direct about the operational shift AI has created for small fund managers. At GV, the back office was handled. Running Plexo means finance, legal, marketing, and ops all land on a limited management fee. His benchmark at the 2023 Anthropic AGM was simple: if AI can do the work of one junior analyst, that would be a meaningful gain. His current read is that the leverage now exceeds that considerably, and the timing is particularly useful for emerging managers who cannot afford to staff up conventionally.

Vice categories and LPA dynamics

On the question of vice investments, Toney's practical starting point is the LPA itself. Most fund documents carry vice clauses, and GP positioning on categories like gambling, crypto, or controlled substances has to be balanced against LP composition. He notes a subset of GPs who have built explicit vice-focused strategies, arguing that limited capital chasing those categories keeps valuations reasonable and preserves upside. His current watch category is peptides, which he no longer considers vice given the regulatory direction under the current administration and growing mainstream acceptance of GLP-1s as a reference point for the broader class.

Every deal, every interview. 5 minutes.

TBPN Digest delivers summaries of the latest fundraises, interviews and tech news from TBPN, every weekday.